论文部分内容阅读
目的:比较分析巴昔利单抗和抗胸腺细胞球蛋白(ATG)2种抗排斥药物在同种异体肾移植早期临床使用的效果。方法:将59例肾移植患者分为2组,ATG组42例使用ATG免疫诱导治疗,巴昔利单抗组17例使用巴昔利单抗免疫诱导治疗。从肾移植术后急性排斥反应发生率、血肌酐恢复正常时间、1~4周血肌酐及尿素氮水平、感染发生率、术后前3d尿量及术后住院时间、住院费用等多方面观察分析两种药物在肾移植术后早期临床应用的效果。结果:巴昔利单抗组患者较ATG组患者急性排斥反应发生率低、血肌酐恢复正常快1、~4周血肌酐及尿素氮水平低、感染发生率低、住院时间短。结论:IL-2可能在肾移植术后排斥反应中发挥更加重要的作用;使用巴昔利单抗可以更好的预防肾移植术后急性排斥反应的发生。
OBJECTIVE: To comparatively analyze the clinical effect of two anti-rejection drugs, including allosteric and anti-thymocyte globulin (ATG), in the early stage of allogeneic kidney transplantation. Methods: Fifty-nine renal transplant recipients were divided into two groups, 42 patients in ATG group were induced by ATG immunization, and 17 patients in basiliximab group were treated with the induction of basilizumab. The incidence of acute rejection after renal transplantation, serum creatinine return to normal time, serum creatinine and urea nitrogen levels 1 to 4 weeks, the incidence of infection, postoperative 3d urine volume and postoperative hospital stay, hospital costs, and many other aspects Analysis of two drugs in the early postoperative renal transplantation clinical effect. Results: The incidence of acute rejection in patients with basiliximab was lower than that in patients with ATG. Serum creatinine returned to normal within 1 week. Serum creatinine and urea nitrogen levels were low at 4 weeks. The incidence of infection was low and the length of hospital stay was short. CONCLUSION: IL-2 may play a more important role in the rejection after renal transplantation. The use of basiliximab can better prevent the acute rejection after renal transplantation.